DeepMind CEO Demis Hassabis at a 2017 event in China.
Source: Alphabet
Alphabet‘s AI lab, DeepMind, cut employee costs by 39% last year, according to a recent filing with a U.K. government agency.
For the 2022 financial year, staff costs and other related expenses were 594.5 million pounds (nearly $731 million), down from 969.4 million pounds (nearly $1.2 billion) in 2021 — translating to an almost 39% reduction in employee costs, per the filing. Following those cuts, in January, DeepMind announced it would shutter its first-ever international artificial intelligence research office in Edmonton, Canada.
DeepMind’s staff budget cuts occurred during the tech industry’s self-proclaimed “year of efficiency,” and Alphabet itself helped lead the charge. In September 2022, CEO Sundar Pichai announced plans to “make the company 20% more productive,” and over the past year Alphabet has conducted mass layoffs, slowed hiring, cut travel and entertainment budgets, paused construction on at least one office campus and reduced investment for experimental projects such as its Area 120 tech incubator.
Following DeepMind’s employee cost cuts in 2022, Alphabet executives discussed plans to allocate resources to key revenue drivers, such as AI, on its first-quarter earnings call of 2023. But part of that decision was bringing AI-focused groups Google Brain and DeepMind under one umbrella with “pooled computational resources.”
“Beginning in the second quarter of 2023, the costs associated with teams and activities transferred from Google Research will move from Google Services to Google DeepMind within Alphabet’s unallocated corporate costs,” Pichai said during a spring earnings call.
DeepMind’s 2022 profit was about 60.9 million pounds (nearly $74.9 million), down from 102.4 million pounds (nearly $126 million) in 2021 — a decrease of more than 40%.
A worsening macroeconomic climate and the collapse of industry giants such as FTX and Terra have weighed on bitcoin’s price this year.
STR | Nurphoto via Getty Images
Bitcoin fell through the $90,000 level overnight, weakened by sell pressure in equities as the crypto market awaits its next catalyst.
The price of bitcoin fell 6% to $88,519, according to Coin Metrics. Earlier, it fell as low as $87,736.
The decline puts the blue chip coin almost 20% off its all-time high reached on President Donald Trump’s inauguration day.
“Equities have faced a few difficult sessions over the last week, with top-performing stocks down many times the index, as markets grapple with increased uncertainty under the new administration,” said Steven Lubka, head of private clients and family offices at Swan Bitcoin. “This pressure has spilled over into bitcoin and crypto markets.”
The S&P 500 on Monday posted a three-day losing streak as it failed to recover from last week’s sell-off, driven by concern over a slowing economy and sticky inflation.
“Ultimately, the lack of visible short-term catalysts and pressure from equities creates an environment for profit-taking and pressure from shorts,” Lubka added.
Stock Chart IconStock chart icon
Bitcoin falls below the key $90,000 level Monday
Bitcoin kicked off the year in rally mode, fueled by optimism about the positive changes the new Trump administration was expected to make for the crypto industry. However, since the President issued his widely anticipated executive order on crypto at the end of January – the contents of which were well received by the industry despite its tamer than hoped for language on a strategic bitcoin reserve – the market has had little to look forward to.
While optimism about the long-term positive impact Trump’s policies could have for crypto remains high, its movements have been and may continue to be dictated by macroeconomic trends.
“From November through January, the market was very enthusiastic about pricing in a crypto-friendly U.S. administration,” said Joel Kruger, market strategist at LMAX Group. “Now it’s a question of waiting for that next catalyst. We know that all of this is in place, and the market is in a bit of a sell-the-fact consolidation sell as it kind of waits.”
The $90,000 level marks the bottom of the narrow range bitcoin has been trading in since the end of November. Analysts have warned that if bitcoin were to meaningfully break below the level, it could see a deeper pullback toward $80,000.
“There is room for bitcoin still to go back down towards the $70,000 to $75,000 area without doing anything to compromise the outlook,” Kruger said, “and we suspect that there will be plenty of demand as we head down towards those levels.”
Lubka said he believes bitcoin will finish digesting this move and resume its long-term move higher by mid-March.
Other cryptocurrencies fared worse on Monday. Ether and Solana’s sol token each tumbled 9%. The broader market of cryptocurrencies, as measured by the CoinDesk 20 index, lost more than 8%.
Don’t miss these cryptocurrency insights from CNBC Pro:
Chegg seen at the New York Stock Exchange on Feb. 13, 2025.
Danielle DeVries | CNBC
Chegg on Monday filed suit in federal district court against Google, claiming that artificial intelligence summaries of search results have hurt the online education company’s traffic and revenue.
The legal move come nearly two years after former CEO Dan Rosensweig said students engaging with OpenAI’s ChatGPT assistant were cutting into Chegg’s new customer growth.
Chegg is worth less than $200 million, and in after-hours trading Monday, the stock was trading just above $1 per share. Chegg has engaged Goldman Sachs and will look at strategic options, including getting acquired and going private, President and CEO Nathan Schultz told analysts on a Monday earnings call.
Chegg reported a $6.1 million net loss on $143.5 million in fourth-quarter revenue, a 24% decline year over year, according to a statement. Analysts polled by LSEG had expected $142.1 million in revenue. Management called for first-quarter revenue between $114 million and $116 million, but analysts had been targeting $138.1 million. The stock was down 23% in extended trading.
Google forces companies like Chegg to “supply our proprietary content in order to be included in Google’s search function,” said Schultz, adding that the search company uses its monopoly power, “reaping the financial benefits of Chegg’s content without having to spend a dime.”
Despite the suit, Chegg has its own AI strategy. It has drawn on Meta’s open-source Llama, as well as models from privately held Anthropic and Mistral, Schultz said. Chegg has also partnered with OpenAI, which the education company views as a competitor, alongside Google. The company reported that 3.6 million students had subscriptions in the fourth quarter, down 21%. Subscriptions include access to AI-powered learning assistance. Chegg also rents and sells textbooks.
AI Overviews, as Google’s artificial intelligence summaries are called, are available in the company’s search engine in over 100 countries, with more than 1 billion users, the company said in October. They show up above links to other pages in search results.
A Google spokesperson told CNBC that the company will defend itself against Chegg’s suit.
“Every day, Google sends billions of clicks to sites across the web, and AI Overviews send traffic to a greater diversity of sites,” the Google spokesperson said.
Chegg claimed that Google drew on Chegg’s collection of 135 million questions and answers on a variety of subjects in its model training data sets.
After training its models, Google can generate content that competes with information that publishers have on offer in search results, Chegg argued in its complaint. The online learning company included a screenshot of a Google AI Overview that borrows details from Chegg’s website but does not attribute the information. However, the relevant Chegg page does show up lower down in search results.
Chegg cited a federal judge’s ruling last August that Googleholds a monopoly in the search market. The decision came after the Department of Justice in 2020 filed its landmark case, alleging that Google controlled the general search market by creating strong barriers to entry and a feedback loop that sustained its dominance.
Hims & Hers Health shares plunged 18% in extended trading on Monday after investors looked past better-than-expected revenue and earnings and focused instead on the disappointing gross margin.
Here’s how the company did, compared to analysts’ consensus estimates from LSEG:
Earnings per share: 11 cents vs. 10 cents expected
Revenue: $481 million vs. $470 millionexpected
Revenue at the telehealth company increased 95% in the fourth quarter from $246.6 million during the same period last year, according to a release.
However, the company’s gross margin, or the profit left after accounting for the cost of goods sold, was 77%, while analysts polled by StreetAccount were expecting 78.4%.
It is the second big stock drop for Hims & Hers in a matter of days. The shares tumbled 26% on Friday after the U.S. Food and Drug Administration announced that the shortage of semaglutide injection products has been resolved.
In May, Hims & Hers started prescribing compounded semaglutide, the active ingredient in Novo Nordisk‘s blockbuster GLP-1 medications Ozempic and Wegovy. The company was a breakout star within the digital health sector in 2024, in part because of the success of its popular new weight loss offering.
The company said its GLP-1 offering generated more than $225 million in revenue in 2024. The stock climbed about 200% for the year.
Compounded drugs are custom-made alternatives to brand-name drugs designed to meet a specific patient’s needs, and compounders are allowed to produce them when brand-name treatments are in shortage. The FDA said Friday that it will start taking action against compounders for violations in the next 60 to 90 days.
Hims & Hers said on the earnings call that as a result, compounded semaglutide will likely not be offered on the platform after the first quarter.
“We will have to start notifying customers in the coming month or two that they will need to start looking for alternative options on the commercial dosing,” Hims & Hers CEO Andrew Dudum said on the call. “I would suspect, just being very direct, that a lot of those patients will try to go into the open market and try to secure a branded option in some form factor.”
Some patients might still be able to access compounded semaglutide if it is clinically necessary, the company added.
The company’s weight loss offerings will primarily be composed of its oral medications and the generic medication liraglutide, which it plans to introduce on its platform this year. Excluding contributions from compounded semaglutide, Hims & Hers said it expects it weight loss offering will generate at least $725 million in revenue in 2025.
Hims & Hers also offers treatments for skin care, mental health, sexual health and hair care.
Revenue for non-GLP-1 products increased 43% to $1.2 billion for the full year, “meeting our previous 2025 revenue target a year early,” Chief Financial Officer Yemi Okupe said in a release.
“The success we are experiencing is a direct reflection of our improving ability to democratize access to high quality, personalized care across each of our specialties,” Okupe said.
Net income climbed to $26.01 million, or 11 cents per share, from $1.25 million, or 1 cent per share, a year prior. The company reported adjusted earnings of $54.1 million, meeting analysts’ estimates, according to StreetAccount.
For the first quarter, Hims & Hers expects to report revenue of $520 million to $540 million, while analysts were expecting $497 million. Adjusted earnings will be between $55 million and $65 million for the period, the company said.
Hims & Hers will host its quarterly call with investors at 5:00 p.m. ET.
— CNBC’s Brandon Gomez contributed to this report.